CAMBRIDGE, Mass., Sept. 11 /PRNewswire/ -- Hemedex, Inc., a privately held
company developing a stream of products to provide clinicians with valuable
new prognostic data by measuring tissue blood flow in multiple clinical
application areas, presented an overview of recent milestones achieved by the
Company, and outlined management's vision for near term development and future
strategic growth, to healthcare industry executives and investors at the
recently held EMT-East Conference.
    Gregory T. Martin, Ph.D., Hemedex Vice President of Research and
Development, described the evolution of the Company's proprietary technology,
and detailed the significant near term development milestones achieved,
including the successful completion of clinical studies involving over 200
neurosurgical and organ transplantation patients.  Dr. Martin stated: "The
measurements made by the Company's technology are a long sought after and
important parameter in understanding and managing critical medical situations,
and prior to the development of our technology, the capability to get
continuous, real time, perfusion measurements in absolute units did not
exist".
    Further, he said that the Company's successful clinical studies in
neurosurgery and organ transplantation will continue at the existing sites in
Europe and Asia, and that new, expanded studies are slated to begin in Q4 2001
at multiple, major medical centers in the U.S. These new clinical studies will
focus not only on neurosurgery and organ transplantation, but also include
indications such as plastic and reconstructive surgery, cardiovascular and
vascular surgery, oncology, and shock monitoring, among others.
    Additionally, the Company will be submitting its first 510(k) application
to the FDA in Q4 2001, and is currently in the process of ramping up its
manufacturing capabilities to meet the expected demand for its perfusion
monitoring devices.
    Dr. Martin released data from both pre-clinical and clinical applications
of the Company's proprietary thermal diffusion technology, which served to
further validate the Company's claims of achieving real-time, minimally
invasive, accurate perfusion measurements, in absolute units, and in multiple,
diverse, medical and surgical indications. As explained by Dr. Martin, the
Company expects worldwide sales of its proprietary perfusion monitoring
technology to begin in early 2002. He described the Company's first strategic
partnership, which is a distribution agreement covering defined indications in
specific Asian markets, and explained that the Company's intent is to form
additional strategic alliances with other healthcare companies that have
synergistic technologies, or dominant market share and critical mass in target
markets.

    About Hemedex, Inc.
    Hemedex, Inc., located in Cambridge, Massachusetts, is a vertically
integrated medical device company that designs, develops and markets minimally
invasive, perfusion-measuring devices that address critical medical problems
in areas that include neurosurgical monitoring, organ transplantation,
cardiovascular monitoring, reconstructive surgery and oncology diagnosis.
Hemedex plans to further apply its proprietary techniques and expertise in
thermal physics, biomaterials, instrumentation and biomedical engineering to
other clinical application areas where it can provide powerful new tools for
physicians, and have a significant impact on the progress of patient therapy
and healing.
    Hemedex's products are based on a proprietary, platform perfusion
quantification technology, licensed from Thermal Technologies, Inc. of
Cambridge, MA, which was originally developed at the Massachusetts Institute
of Technology with funding from the National Institute of Health.

     CONTACT: Michael T. McCartin, 617.577.1759, x145;
              E-mail: mccartin@hemedex.com

Link to this page: